The feasibility and safety of naked mRNA vaccines was first demonstrated in a phase I/II trial in 15 metastatic melanoma patients using intradermally injected autologous tumor mRNA and GM-CSF [93]. The gene discussed is CSF2; the disease is neoplasm.